BeiGene, Ltd. (ONC)vsVivoSim Labs, Inc. (VIVS)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
VIVS
VivoSim Labs, Inc.
$1.62
-2.41%
HEALTHCARE · Cap: $4.33M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 3762599% more annual revenue ($5.34B vs $142,000). ONC leads profitability with a 5.4% profit margin vs 0.0%. VIVS trades at a lower P/E of 0.9x. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
VIVS
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
+84.0%
Fair Value
$11.97
Current Price
$1.62
$10.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -51.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : VIVS
The strongest argument for VIVS centers on P/E Ratio, Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : VIVS
The primary concerns for VIVS are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while VIVS is a value play — different risk/reward profiles.
VIVS carries more volatility with a beta of 1.32 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 27/100) and 32.8% revenue growth. VIVS offers better value entry with a 84.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →VivoSim Labs, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?